Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1992 Jul;83(7):761–768. doi: 10.1111/j.1349-7006.1992.tb01977.x

Therapeutic Effect of Ansamitocin Targeted to Tumor by a Bispecific Monoclonal Antibody

Kayoko Okamoto 1, Kaori Harada 1, Shuichi Ikeyama 1, Susumu Iwasa 1,✉
PMCID: PMC5918935  PMID: 1517150

Abstract

We have constructed a murine hybrid hybridoma that secretes a bispecific monoclonal antibody (mAb) by fusing a hybridoma secreting an anti‐ansamitocins mAb with a hybridoma secreting an anti‐human transferrin receptor (TfR) mAb that binds to human A431 epidermoid carcinoma cells. The bispecific mAb, reactive to both ansamitocins and TfR, was purified by a combination of hydrophobic column chromatography and hydroxyapatite high‐performance liquid chromatography, and evaluated in in vivo experiments using human tumor cell‐implanted nude mice. Ansamitocin P‐3 targeted through one of the antigen combining sites of the bispecific mAb was potentially more effective in suppressing the growth of established A431 tumor xenografts implanted on nude mice than unconjugated ansamitocin P‐3 or the immunoconjugate of ansamitocin P‐3 and monospecific anti‐ansamitocins antibody, and the targeted ansamitocin P‐3 finally eradicated the tumor mass. The bispecific mAb also played an important role in reducing such undesirable side‐effects of ansamitocin P‐3 as the loss of body weight, the damage to liver functions and the decrease in the number of white blood cells.

Keywords: Key words, Hybrid hybridoma, Bispecific antibody, Ansamitocin P‐3, Human transferring

Full Text

The Full Text of this article is available as a PDF (540.4 KB).

REFERENCES

  • 1. ) Higashide , E. , Asai , M. , Ootsu , K. , Tanida , S. , Kozai , Y. , Hasegawa , T. , Kishi , T. , Sugino , Y. and Yoneda , M.Ansamitocin, a group of novel maytansinoid antibiotics with antitumor properties from Nocardia . Nature , 270 , 721 – 722 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Ootsu , K. , Kozai , Y. , Takeuchi , M. , Ikeyama , S. , Igarashi , K. , Tsukamoto , K. , Sugino , Y. , Tashiro , T. , Tsukagoshi , S. and Sakurai , Y.Effects of new antimitotic antibiotic, ansamitocins, on the growth of murine tumors in vivo and on the assembly of microtubules in vitro . Cancer Res. , 40 , 1707 – 1717 ( 1980. ). [PubMed] [Google Scholar]
  • 3. ) Tanida , S. , Hasegawa , T. and Higashide , E.A simple method for determining antitubulinic activities of ansamitocins and related compounds using a cilia regeneration system with decililated Tetrahymena . Agric. Biol. Chem. , 44 , 1847 – 1853 ( 1980. ). [Google Scholar]
  • 4. ) Kawai , A. , Akimoto , H. , Hashimoto , N. and Nomura , H.Chemical modification of ansamitocins. I. Synthesis and properties of 4,5 ‐deoxymaytansinoids . Chem. Pharm. Bull , 32 , 2194 – 2199 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Akimoto , H. , Kawai , A. , Hashimoto , N. and Nomura , H.Chemical modification of ansamitocins. II. Synthesis of 3‐epimaytansinoids via 3‐maytansinones . Chem. Pharm, Bull. , 32 , 2565 – 2570 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Kawai , A. , Akimoto , H. , Kozai , Y. , Ootsu , K. , Tanida , S. , Hashimoto , H. and Nomura , H.Chemical modification of ansamitocins. III. Synthesis and biological effects of 3‐acyl ester of maytansinol . Chem. Pharm. Bull , 32 , 3441 – 3451 ( 1984. ). [PubMed] [Google Scholar]
  • 7. ) Milstein , C. and Cuello , A. C.Hybrid hybridoma and their use in immunohistochemistry . Nature , 305 , 537 – 540 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Suresh , M. R. , Cuello , A. C. and Milstein , C.Advantages of bispecific hybridomas in one‐step immunocytochemistry and immunoassays . Proc. Natl. Acad. Sci. USA , 83 , 7989 – 7993 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Karawajew , L. , Behrsing , O. , Kaiser , G. and Micheel , B.Production and ELISA application of bispecific monoclonal antibodies agaist fluorescein isothiocyanate (FITC) and horseradish peroxidase (HRP) . J. Immunol. Methods , 111 , 95 – 99 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Staerz , U. D. , Kanagawa , O. and Bevan , M. J.Hybrid antibodies can target sites for attack by T cells . Nature , 314 , 628 – 631 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Lanzavecchia , A. and Scheidegger , D.The use of hybrid hybridomas to target human cytotoxic T lymphocytes . Eur. J. Immunol , 17 , 105 – 111 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Clark , M. and Waldmann , H.T‐Cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies . J. Natl. Cancer Inst. , 79 , 1393 – 1401 ( 1987. ). [PubMed] [Google Scholar]
  • 13. ) Fanger , M. F. , Segal , D. M. and Romet‐Lemonne , J.‐L.Bispecific antibodies and targeted cellular cytotoxicity . Immunol Today , 12 , 52 – 54 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Corvalan , J. R. F. and Smith , W.Construction and characterisation of a hybrid‐hybrid monoclonal antibody recognizing both carcinoembryonic antigen (CEA) and vinca alkaloids . Cancer Immunol. Immunother. , 24 , 127 – 132 ( 1987. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. ) Corvalan , J. R. F. , Smith , W. , Gore , V. A. , Brandon , D. R. and Ryde , P. J.Increased therapeutic effect of vinca alkaloids targeted to tumor by a hybrid‐hybrid monoclonal antibody . Cancer Immunol Immunother. , 24 , 138 – 143 ( 1987. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. ) Corvalan , J. R. F. , Smith , W. and Gore , V. A.Tumor therapy with vinca alkaloids targeted by a hybrid‐hybrid monoclonal antibody recognising both CEA and vinca alkaloids . Int. J. Cancer: Suppl. , 2 , 22 – 25 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Tsukada , Y. , Ohkawa , K. , Hibi , N. , Tsuzuki , K. , Oguma , K. and Satoh , H.The effect of bispecific monoclonal antibody recognizing both hepatoma‐specific membrane glycoprotein and anthracycline drugs on the metastatic growth of hepatoma AH66 . Cancer Biochem. Biophys. , 10 , 247 – 256 ( 1989. ). [PubMed] [Google Scholar]
  • 18. ) Nitta , T. , Sato , K. , Yagita , H. , Okumura , K. and Ishii , S.Preliminary trial of specific targeting therapy against malignant glioma . Lancet , 335 , 368 – 371 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Tada , H. , Toyoda , Y. and Iwasa , S.Bispecific antibody‐producing hybrid hybridoma and its use in one‐step immunoassays for human lymphotoxin . Hybridoma , 8 , 73 – 83 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Honda , S. , Ichimori , Y. and Iwasa , S.A human hybrid hybridoma producing a bispecific monoclonal antibody that can target tumor cells for attack by Pseudomonas aeruginosa exotoxin A . Cytotechnology , 4 , 59 – 68 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Kurokawa , T. , Iwasa , S. and Kakinuma , A.Enhanced fibrinolysis by a bispecific monoclonal antibody reactive to fibrin and tissue plasminogen activator . Bio/Technology , 7 , 1163 – 1167 ( 1989. ). [Google Scholar]
  • 22. ) Kurokawa , T. , Iwasa , S. , Kakinuma , A. , Stassen , J.‐M. , Lijnen , H. R. and Collen , D.Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase‐type plasminogen activator . Thromb. Haemostasis , 66 , 684 – 693 ( 1991. ). [PubMed] [Google Scholar]
  • 23. ) Iwasa , S. , Kondo , K. , Miya , T. and Takeda , K.Enzyme immunoassay of β‐adrenergic agent using β‐galactosidase as label . Immunopharmacology , 1 , 3 – 12 ( 1978. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Seligman , P. A. , Schleiche , R. B. and Allen , R. H.Isolation and characterization of the transferrin receptor from human placenta . J. Biol. Chem. , 254 , 9943 – 9946 ( 1979. ). [PubMed] [Google Scholar]
  • 25. ) Gefter , M. L. , Margulies , D. H. and Scharff , M. D.A simple method for polyethylene glycol‐promoted hybridization of mouse myeloma cells . Somatic Cell Genet. , 3 , 231 – 236 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Karawajew , L. , Micheel , B. , Behrsing , O. and Gaestel , M.Bispecific antibody‐producing hybrid hybridomas selected by a fluorescence activated cell sorter . J. Immunol Methods , 96 , 265 – 270 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Iwasa , S. , Konishi , E. , Kondo , K. , Suzuki , T. , Akaza , H. and Nüjima , T.Selective cytotoxicity of drug‐monoclonal antibody conjugates against murine bladder tumor cells . Chem. Pharm. Bull , 35 , 1128 – 1137 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Klausner , R. D. , Ashwell , G. , Remswonde , J. , Harford , J. B. and Bridges , K. R.Binding of apotransferrin cycle . Proc. Natl. Acad. Sci. USA , 80 , 2263 – 2266 ( 1983. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. ) Sakihama , N. , Kitagawa , Y. , Kitazume , Y. and Shin , M.Application of Toyopearls to purification of Azotobacter flavodoxin . Agric. Biol. Chem. , 47 , 2917 – 2919 ( 1983. ). [Google Scholar]
  • 30. ) Tada , H. , Shiho , O. , Kuroshima , K. , Koyama , M. and Tsukamoto , K.An improved colorimetric assay for interleukin 2 . J. Immunol Methods , 93 , 157 – 165 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Geran , R. I. , Greenberg , N. H. , Macdonald , M. M. , Schumacher , A. M. and Abbott , B. J.Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition) . Cancer Chemother. Rep., Part 3 , 3 , 1 – 61 ( 1972. ). [Google Scholar]
  • 32. ) Yamaoka , K. , Tanigawara , Y. and Uno , T.A pharmacokinetic analysis program (Multi) for microcomputer . J. Pharmacobio-Dyn. , 4 , 879 – 885 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Blair , A. H. and Ghose , T. I.Linkage of cytotoxic agents to immunoglobulin . J. Immunol Methods , 59 , 129 – 143 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 34. ) Ohkawa , K. , Hibi , N. and Tsukada , Y.Evaluation of a conjugate of purified antibodies against human AFP‐dextran‐daunorubicin to human AFP‐producing yolk sac tumor cell lines . Cancer Immunol Immunother. , 22 , 81 – 86 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. ) Shin , L. B. , Sharkey , R. M. , Primus , F. J. and Goldenberf , D. M.Site‐specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier . Int. J. Cancer , 41 , 832 – 839 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Chari , R. V. , Martell , B. A. , Gross , J. L. , Cook , S. B. , Shah , S. A. , Blattler , W. A. , Mckenzie , S. J. and Goldmacher , V. S.Immunoconjugates containing novel maytansinoids: promising anticancer drugs . Cancer Res. , 52 , 127 – 131 ( 1992. ). [PubMed] [Google Scholar]
  • 37. ) Carlsson , J. , Drevin , H. and Axen , R.Protein thiolation and reversible protein‐protein conjugation . Biochem. J. , 173 , 723 – 737 ( 1978. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. ) Trowbridge , I. S. and Omary , M. B.Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin . Proc. Natl Acad. Sci. USA , 78 , 3030 – 3043 ( 1981. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. ) Trowbridge , I. S. and Lopez , F.Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro . Proc. Natl Acad. Sci. USA , 79 , 1175 – 1179 ( 1982. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. ) Mendelsohn , J. , Trowbridge , I. and Castagnola , J.Inhibition of human lymphocyte proliferation by monoclonal antibody to transferrin receptor . Blood , 62 , 821 – 826 ( 1983. ). [PubMed] [Google Scholar]
  • 41. ) Haynes , B. F. , Hemler , M. , Cotner , T. , Mann , D. L. , Eisenbarth , G. S. , Strominger , J. L. and Fauci , A. S.Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation . J. Immunol. , 127 , 347 – 351 ( 1981. ). [PubMed] [Google Scholar]
  • 42. ) Shindelman , J. E. , Ortmeyer , A. E. and Sussman , H. H.Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells . Int. J. Cancer , 27 , 329 – 334 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 43. ) Vodinelich , L. , Sutherland , R. , Schneider , C. , Newman , R. and Greaves , M.Receptor for transferrin may be a “target” structure for natural killer cells . Proc. Natl. Acad. Sci. USA. 80 , 835 – 839 ( 1983. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. ) Trowbridge , I. S. and Domingo , D. L.Anti‐transferrin receptor monoclonal antibody and toxin‐antibody conjugates affect growth of human tumor cells . Nature , 294 , 171 – 173 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 45. ) Betra , J. K. , Jinno , Y. , Chaudhary , V. K. , Kondo , T. , Willingham , M. C. , FitzGerald , D. J. and Pastan , I.Anti‐tumor activity in mice of an immunotoxin made with anti‐transferrin receptor and a recombinant form of Pseudomonas exotoxin . Proc. Natl. Acad. Sci. USA , 86 , 8545 – 8549 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES